When could the personalised melanoma vaccine be licensed, and what are the caveats?

Fergus Walsh said he thinks the vaccine is likely to be licensed next year, probably first in the US, then in Europe and perhaps the UK. He named two caveats: nobody yet knows its effect on long-term survival, and making a separate drug for every patient will be very expensive. The jab can also cause side effects.

Walsh said patients would likely see more healthy time with their families as worth the price.

▸In their words

“And secondly, this is going to be really expensive.” Fergus Walsh · at 4:37 — open in the transcript →

Source: our own transcription of the episode. The full conversation is on Global News Podcast (2026-10-31). Read the whole episode summary →

▸More from this episode

Q1How much did the personalised melanoma vaccine cut the risk of cancer returning in the global trial?Q2How does the personalised mRNA melanoma vaccine work, according to the BBC's Fergus Walsh?Q4How did Nigerian singer Steve Monite find out he had become famous as the King of Boogie?Q5How did neighbours in Huntsville, Alabama make an autistic boy's doorbell birthday wish come true?Q6How does the Parkinson's UK Brain Bank work, and who can donate?Q7Why does Kibera Ballet School teacher Mike Wamaya use ballet to help children in Nairobi?Q8How did conservationist Aristide Kamla clear Lake Ossa's invasive weed to protect African manatees?

Transcribe your links. Paste a YouTube, Google Drive or podcast link and WhipScribe gives you the transcript. Transcribe a link →